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ABSTRACT. Asbestos fibers are naturally occurring silicates that have been extensively used in 
the past, including in house construction but, because of their toxicity, their use has been banned 
in sixty-three countries. Despite this, more than one million metric tons of asbestos are still 
consumed annually in countries where asbestos use has not been banned.  Asbestos-related 
disease incidence is still increasing in several countries, including those countries that banned the 
use of asbestos more than thirty years ago. We highlight here recent knowledge obtained in 
experimental models about the mechanisms leading to tumor development following asbestos 
exposure, including genetic and epigenetic changes. Importantly, the landscape of alterations 
observed experimentally in tumor samples is consistent with alterations observed in clinical 
tumor samples; therefore, studies performed on early/pre-cancer stages should help inform 
secondary prevention, which remains crucial in the absence of an efficient primary prevention.  
Knowledge gathered on asbestos should also help address future challenges, especially in view 





In this perspective our aim is to document that asbestos, although banned in several countries, 
still represents a threat for human health. After providing information on asbestos exposure, we 
summarize current knowledge about the mechanisms involved highlighting recent data where 
similarities with some engineered nanomaterials has been observed. We conclude with open 
questions that remain to be addressed and suggest future priorities. 
Asbestos production and exposure 
Asbestos fibers are naturally occurring silicates and their properties include high mechanical 
and thermal stability, high tensile strength and flexibility, low thermal and electrical 
conductivity, high absorbency and resistance to acids and bases. The economically relevant ones 
include amphiboles (crocidolite, amosite, tremolite,anthophyllite and actinolite) and the most 
commonly used chrysotile, which is a serpentine fiber. Asbestos can be mixed with cement and 
used in construction and in the past has been widely used in shipbuilding, in household 
appliances, as a soil conditioner, in cigarette filters, brake linings and theatre curtains. 
Annual asbestos production and consumption had peaked in 1980 at approximately 4.8 million 
metric tons, then decreased to approximately 1.3-1.4 million metric tons by 2016, with Russia 
being the biggest producer (692,000 tons) followed by Kazakhstan, China and Brazil 
(contributing for around 200,000 tons), while the biggest consumers are India (308,000 tons), 
China (288,000 tons), Russia (234,000 tons), followed by Brazil (120,000 tons) and Indonesia 
(114,000 tons)1. In comparison, it is important to note details regarding the use of asbestos in the 
United States of America (USA), which stopped all production of asbestos in 2002. In 2017, 
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domestic consumption of imported asbestos minerals was estimated to be 300 tons. It was mostly 
used in chloralkali industry, which uses asbestos to manufacture semipermeable diaphragms that 
prevent chlorine generated at the anode of an electrolytic cell from reacting with sodium 
hydroxide generated at the cathode1.  In addition, an unknown quantity of asbestos was imported 
within manufactured products1.  
In 1997, it was estimated that 20% of buildings in the US still contain products made from 
chrysotile asbestos2. Therefore, release of fibers can result from decay, renovation or demolition 
of these structures. Past industrial production of materials containing asbestos may also lead to 
contamination of the environment and community exposure (reviewed in 3). For example, in 
Libby, Montana, US, vermiculite ore was contaminated with as much as 25% amphibole 
asbestos and a significant rates of asbestos-related diseases have been observed among 
community residents who never worked in the vermiculite mining operations.  
Based on the recognized association of asbestos exposure with cancer development, which 
originated from observations done in the 1960’s, the use of asbestos is currently banned in 63 
countries (http://www.ibasecretariat.org/alpha_ban_list.php). 
Based on the pioneering work of Stanton 4, the toxicity of asbestos and asbestos-like fibers is 
known to be determined by dose, aspect ratio (length/diameter), biopersistence and surface 
reactivity (reviewed in 5, 6). The so called classical ‘Fiber Pathogenicity Paradigm’ is a 
structure:toxicity model that predicts thinness, length, and biopersistence as key factors that 
determine fiber pathogenicity 7.  
According to the World Health Organization (WHO), respirable fibers have a length above 5 
μm, a diameter below 3 μm, and an aspect ratio (length/diameter) above or equal to 3. The 
occupational recommended exposure limit by the Occupational Safety and Health 
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Administration (OSHA) is between 0.2 and 1 respirable fiber/cm3 for an 8 h time weighed 
average for synthetic mineral fibers (https://www.osha.gov/SLTC/syntheticmineralfibers/table.html) 
and 0.1 fiber/cm3  for asbestos (https://www.osha.gov/Publications/osha3095.html). 
Lower values exist in other countries (https://www.dguv.de/ifa/gestis/gestis-internationale-
grenzwerte-fuer-chemische-substanzen-limit-values-for-chemical-agents/index-2.jsp). Therefore, 
assuming an inhalation of ca 6 Mio cm3/d, and knowing that it has been estimated that 1 µg can 
correspond, depending on the size of fibers, to up to 107 fibers 8, 0.6 µg of respirable fibers are 
possibly inhaled/day in occupational settings. The fibers then deposit in the nasal, pharyngeal, 
laryngeal tract or tracheo-bronchial and alveolar tract, depending on whether their aerodynamic 
diameter is larger or smaller than 0.1 μm (reviewed in 9). Inhaled fibers are cleared by 
physiological processes, including phagocytosis by macrophages for fibers shorter than 10-20 
μm, and by the lymphatic system. Determination of lung and pleural deposits of asbestos fibers 
is complex and has only been documented in a few studies (reviewed in 10 11). Asbestos fibers can 
adsorb xenobiotics and the deposition of endogenous iron, protein, and mucopolysaccharide on 
biopersistent fibers results in the formation of ferruginous or asbestos bodies.  
For all the reasons highlighted above, it appears that asbestos still represents a worldwide 
threat and awareness about its toxicity (as discussed below) needs to be of public concern. 
 
Asbestos-related diseases 
Exposure to asbestos is linked to non-malignant diseases and cancer. Wagner12 pioneered 
epidemiological studies investigating asbestos-related malignant mesothelioma, but the 
relationship between asbestos exposure and asbestosis and lung cancer has been known since the 
early past century13, 14 (reviewed in 15). Non-malignant diseases include pleural plaques, a form of 
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localized area of pleural thickening, pleural fibrosis, benign effusion and asbestosis 16. 
Asbestosis, is characterized by lung inflammation and scarring and life expectancy averages 3 to 
5 years after diagnosis. Asbestosis has been shown to cause death in 10% of insulation workers 
17. Although as a result of regulated control of asbestos exposure in the workplace the prevalence 
of asbestosis has decreased, the estimate of the global number of asbestosis deaths from the 
Global Burden of Disease (determined in 2016) is 349518. Worldwide asbestosis death rate is 




Figure 1. Asbestosis mortality rates are still increasing worldwide including in high-income countries 
(https://vizhub.healthdata.org/gbd-compare/ , accessed July 31 2018) 
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. 
The association of pleural plaques with pleural mesothelioma is still not clear.  Pleural plaques 
have been considered as “sentinel events“ for asbestos exposure, although the presence of pleural 
plaques has no correlation with the development of mesothelioma 20. However, a study has 
shown a statistically significant association between mesothelioma and pleural plaques  21.  
 
Malignant diseases related to asbestos exposure (reviewed in 17) include lung cancer, 
mesothelioma, ovarian cancer, and laryngeal cancer. More recently, data also support the 
association between occupational exposure to asbestos and stomach and colorectal carcinomas22, 
23.  All these cancers are found in the scientific literature to be in excess among asbestos-exposed 
individuals. 
Since the seminal experiments of Wagner24, exposure to asbestos has been clearly identified as 
cause of mesothelioma. Malignant mesothelioma is a rapidly fatal and highly resilient tumor 
arising in the thin layer of tissue known as the mesothelium, which has mesodermal origins and 
covers many of the important internal organs like the lungs (pleural mesothelioma), peritoneal 
cavities (peritoneal mesothelioma), the sacs surrounding the heart (pericardial mesothelioma) 
and the testis (tunica vaginalis mesothelioma). Malignant pleural mesothelioma (MPM) is the 
most common type accounting for about 80% of cases, because most exposures result from 
inhalation. However, an excess of peritoneal mesotheliomas is also found in asbestos-exposed 
workers. Although MPM is a relatively rare cancer in the general population, individuals 
occupationally exposed to asbestos, are at a higher risk for contracting this disease25-31. It is 
estimated that 1.3 million workers in the USA and 125 million people worldwide have a history 
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of asbestos exposure32. Considering the rising use of asbestos in developing countries, it is likely 
that this number will continue to increase in the future3, 17, 33. Familial, genetic and environmental 
factors may also contribute to the incidence of MPM34-37.  
The incidence of MPM in 2011-2012 was around 3/100,000 in men in Belgium, Switzerland 
and Denmark and 4/100,000 in the Netherlands, while it is between 1 and 2/100,000 in Austria 
and Sweden. The incidence in women, while similar in all those countries, is much lower (ca 
0.5/100,000) (Figure 2). 
 
Figure 2. Mesothelioma international comparison 2011-2012. Corresponds to the ICD-10 Code C45 
with the exception of Sweden and Denmark (C38.4). Data from FSO/NICER 2008-2012 were used for 
Switzerland (C38.4, C45.0). Belgium and Sweden: no comparable data on mortality. Norway, Italy and 






The rate reported for the UK is higher with a similar difference between men and women 
(Figure 3). 
 
Figure 3. Mesothelioma mortality rates have increased by 887% in Great Britain since the early 1970s. 
Cancer Research UK; http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/mesothelioma/mortality#heading-Two 




Figure 4. Mesothelioma mortality rates are still increasing worldwide including in high-income 
countries (https://vizhub.healthdata.org/gbd-compare/ , accessed July 31 2018) 
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.  
The annual global health care cost associated with asbestos-related cancer has been estimated 
to amount to 2.4-3.9 billion USD worldwide 39, which, although 100-fold lower compared to 
smoking attributable illnesses 40, will not decrease soon taking into account those countries that 
still produce/ consume asbestos. In addition, even in countries that never produced asbestos, such 
as Iceland 41, and others where asbestos was banned early, the incidence of MPM is still rising. In 
Sweden, where asbestos was banned in 1982, no clear effect on the occurrence of mesothelioma 
has been found in a Swedish Nordic Occupational Cancer Study42. An additional important factor 
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is that the incidence of mesothelioma is higher and plateauing in a population (Figure 5) age 




Figure 5. Pleural mesothelioma by age, in Switzerland 2008-2012. * New cases estimated on the basis 




The increase in mesothelioma incidence rate in older populations has been used as additional 
support for the long latency period between known asbestos exposure and cancer development 43 
that may contribute to the observed continued increase in mesothelioma incidence. Of the 
worldwide mesothelioma deaths reported to the WHO between 1998 and 2008, 54% occurred in 
Europe 44 highlighting the problem of underreporting in some countries, as it is often observed 
with rare diseases that are difficult to diagnose. In addition, a specific International Classification 
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of Diseases (ICD) code for mesothelioma, which is the foundation for global statistics, has been 
available only since the tenth revision (ICD10), which was first implemented in 1994. Many 
countries have not yet implemented ICD10, and the accuracy of coding varies by country.  
Mechanisms of MPM development 
The mechanism of development of MPM after exposure to asbestos fibers is not fully 
elucidated but several hypotheses can be suggested based on experimental data and observations 
in clinical samples45. The aim of this perspective is first to briefly summarize these data, some of 
which has been extensively detailed in several reviews 7, 46-52.  
Inhaled asbestos fibers pass the alveolar barrier and reach the lung interstitium. During this 
process they transiently activate signaling pathways such as the NOD-like receptor protein 3 
(NLRP3) inflammasome 53 , or other yet uncharacterized pathways, in alveolar and/or interstitial 
macrophages and the transcription factor nuclear Factor Kappa B subunit 1 (NF-κB) in lung 
epithelial cells, resulting in the release of pro-inflammatory cytokines. The mechanism 
underlying the passage of fibers from the lung interstitium to the pleural space is matter of 
controversy 7, 48; however, what seems generally accepted is that fibers accumulate at the site of 
pleural fluid drainage. The latter takes place through the lymphatic stomata which are ovoid or 
round openings of 2 to 10 µm in diameter found on small selected surface areas of the parietal 
pleura, particularly the anterior lower chest wall and mediastinum directed part 54. No stomata 
are present on the visceral pleura. The accumulation of fibers at parietal pleura  supports the 
concept that mesothelioma originates primarily from the this site 55. The persistent accumulation 
of fibers into the pleural space results in chronic damage and inflammation of the mesothelial 
surface lining cells, or the immediate submesothelial layer, respectively. Although it is not 
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known which cells are at the origin of this cancer there has been one study which supports the 
concept of multiclonality 56.  
Genotoxic initiation processes (reviewed in 8, 57) and/or an epigenetic mechanism mediate the 
carcinogenic activity of asbestos. Asbestos fibers phagocytosed by dividing cells interfere with 
mitosis 20. Asbestos fibers induce an increase in DNA breaks in vitro resulting in ~50% increase 
in loss of heterozygosity in exposed lymphocytes 58 or micronuclei formation in exposed lung 
epithelial cells 59.  The capacity of asbestos to generate DNA breaks is strongly linked to the 
presence of fiber-associated iron and reactive oxygen species (ROS) generation 60. In vivo, 
asbestos induced two to three-fold increased levels of 8-hydroxydeoxyguanosine compared to 
basal tissue levels61, 62.  A 50% increase of G to T transversion63, or mere doubling of 
spontaneous mutations appearing 16 weeks after exposure 64, have been described in  lacI 
transgenic rats depending on exposure route, indicating that most probably also in vivo DNA 
breaks are the main genotoxic consequence of iron-loaded asbestos fibers. The consequence, at 
least in vitro, of this overall low but persistent DNA damage in non-neoplastic cells is 
senescence 65, characterized by stable cell cycle arrest with active metabolism. Senescence is a 
delayed stress response involving multiple effector mechanisms including DNA damage 
response 66, 67  epigenetic regulation 68 , autophagy 69 and senescence-associated secretion 
phenotype 70-72, 73 . It has been proposed that the senescence-associated secretory phenotype, 
might stimulate the immune system to clear senescent cells (reviewed in 74). One reason why 
senescent cells have to be eliminated is that they can secrete mitogenic factors 71. Senescent 
phenotype, due to low level of persistent DNA damage in mesothelial cells which are not 
efficiently cleared by the immune system, may lead to epigenetic effects. This is supported by 
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the recent observation that carcinogenic asbestos fibers induce methylation of the cyclin-
dependent kinase inhibitor 2A (CDKN2A) promoter 62 in the early stages of tumor development.  
In addition, Rehrauer et al75 observed, in samples from experimental animals, that asbestos 
increased the levels of RNA mutations and the most abundant changes were A to G mutations, 
likely resulting from hydrolytic deamination of adenosine downstream of adenosine-deaminase 
acting on RNA (Adar) activity 76 (I is detected as G in RNA-sequencing). Interestingly, Adar is a 
target of the interferon type 1 pathway, which acts as a negative feedback regulator to avoid 
autoimmunity, an effect which has recently been linked to asbestos amphiboles (reviewed in 77) 
and further highlighting the immunotoxicity of asbestos.  
The reviews mentioned above and 78 summarize all the experimental evidence of tissue repair 
stimulation following exposure to asbestos fibers or mesothelium injury.  In a recent study 
comparing pre-cancer and cancer stage in mice following exposure to crocidolite fibers, it was 
documented that chronic tissue repair activates stem cell signaling pathways to regenerate the 
tissues 75.  Because of persistent stimulation, oncogenic events have been postulated to occur in 
such conditions, leading to the development of a tumor 79. Stem cells may be involved in this 
(these) process(es). Two scenarios can be imagined. On one hand, it is possible that a 
differentiated mesothelial cell starts dividing and dedifferentiates re-activating stem cell 
signaling present during embryonic development. On the other hand, mesothelial precursors 
might be present. The only embryonic mesothelial precursor population described to date is a 
Mesothelin+CD90+CD34+ population 80 and an increase in a cell population with similar 
characteristics has been described in the peritoneal lavage collected after intraperitoneal 
administration of crocidolite fibers 75. However, lineage-tracing studies would be necessary to 
learn whether these cells are at the origin of mesothelioma.  
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In order to understand which pathways are important for mesothelioma development, an 
approach complementary to experimental exposure is the analysis of clinical samples. A recent 
large-scale study, based on pathological samples, has comprehensively characterized the most 
frequent genetic alterations in MPM 81, which involve tumor suppressor inactivation, mediated 
by multiple mechanisms that include single nucleotide variants, copy number losses, gene 
fusions and splicing alterations. According to the catalogue of somatic mutations in cancer 
(COSMIC, cancer.sanger.ac.uk version 85), the four most commonly mutated genes in MPM 
are: the tumor suppressor CDKN2A, followed by BAP1 (BRCA1-associated protein 1), NF2 
(neurofibromatosis type 2) and TP53, and mice deficient for one of these genes display an 
increased incidence of mesothelioma after exposure to asbestos fibers 82-86. Pathways most altered 
include histone methylation, as well as the Hippo signaling pathways (see below). Compared to 
other cancer MPM display a relatively low number of point mutations in cancer genes, however 
there is a global tumor suppressor inactivation, which is associated with promoter CpG 
methylation, asbestos burden and worst clinical outcome 87. 
CDKN2A/B 
Genetic alterations in the chromosomal region including CDKN2A (INK4a/ARF) and CDKN2B 
have been observed in 82% and 76% respectively of human and 56% and 60% respectively of 
experimental mouse mesotheliomas 88 . Human mesotheliomas lack the expression of the 
INK4a/ARF locus-encoded P16INK4A and P14ARF proteins 89, 90 due to gene deletion 91, 92, 93 or 
methylation 94, 95, 96. Moreover, CDKN2A loss has been shown to be associated with shorter 
patient survival97-99, and with non-epithelioid histology100.  
BAP1 
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Somatic BAP1 mutations in MPM were first described by Bott et al. and at about the same 
time Testa et al. reported on germline BAP1 mutations predisposing to several cancers including 
malignant mesothelioma and renal cancers, which are derived from the mesodermal lineage, but 
also uveal melanoma 34, 101.  Nowadays the disorder is referred to as BAP1 tumor predisposition 
syndrome in the Online Mendelian Inheritance in Man (https://www.omim.org/) database 102. The 
prevalence of germline mutations in sporadic malignant pleural mesothelioma patients is around 
1-2% 103-106. Therefore, germline BAP1 mutation seem to have a minor role in the pathogenesis of 
sporadic malignant pleural mesothelioma. 
BAP1 protein has multiple functions and somatic mutations might play a role in the neoplastic 
process. Contrary to CDKN2A, BAP1 mutations appear be associated with improved patient 
survival 107,108. BAP1 is part of deubiquitinating enzymes, which remove ubiquitin from different 
targets, thereby opposing the function of E3 ubiquitin ligases 109;101;110. BAP1-deficient cells are 
sensitive to ionizing radiation (IR) and poly(ADP-ribose) polymerase inhibition 111;112. 
Additionally, BAP1 is recruited to double-strand break sites and it is suggested to regulate 
proteins involved in homologous recombination, such as Breast Cancer 1 (BRCA1) and RAD51 
recombinase 112;113. Moreover, proteomic analyses revealed that BAP1 is phosphorylated upon 
DNA damage on ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related 
(ATR) kinases consensus sites 114, 115. Phosphorylation on multiple sites seems to be 
advantageous for cell survival after IR 112. BAP1 dimer was found to form two different 
complexes with the transcriptional regulators ASXL1 and ASXL2, human homologs of 
Drosophila additional sex combs, which are both able to deubiquitinate histone 
monoubiquitinated at K119 (H2Aub) 116;117;118. H2Aub is involved in transcriptional regulation, 
frequently correlated with gene silencing and it additionally occurs at sites of DNA damage and 
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is important for X chromosome inactivation 119, 120. However, BAP1 activity may result in gene 
silencing since by forming a complex with Forkhead Box K2 (FOXK2) transcription factor it 
leads to repression of some FOXK2 target genes 121. BAP1 was also found to be involved in 
metabolism by the stabilization of peroxisome proliferator activator receptor-γ coactivator 1α 
protein, a master regulator of mitochondrial biogenesis and promoter of oxidative metabolism 
122;123. In summary, BAP1 controls several signaling pathways and its function might context 
dependent. 
NF2 
The NF2 gene was discovered by mapping hereditary disease Neurofibromatosis type 2 that 
predisposes to acustic neuromas, neurofibromas and meningiomas. Mutations in the NF2-
encoded tumor suppressor Merlin, have been found in 40% of human MPM 124,125,126, 127. 
Mesotheliomas develop more frequently after inactivation of one Nf2 allele, as compared to 
wild-type animals in mice experimentally exposed to asbestos fibers 82, 83. Moreover, the 
remaining Nf2 allele is lost, indicating that the Nf2 function alterations have a “driver” role in 
asbestos-induced mesothelioma 82 when accompanied by a loss of Ink4a/Arf 128 and Cdkn2b 83. 
The essential role of loss of cell cycle control and NF2 function in mesothelioma development 
has been confirmed in experimental animal models where Nf2 was inactivated by adeno-Cre 
infection of the mesothelial cells lining the thoracic cavity in a “permissive” (Ink4a/Arf-
deficient) and/or p53 deficient background 129.  
The reason why NF2 is an ideal oncogenic target during the development of MPM is that NF2 
translocates into the nucleus, where it inhibits the cullin-RING E3 ubiquitin ligase 4 (CRL4) and 
as a result controls a subset of Hippo pathway target genes 130. Recent data 81 has confirmed that 
NF2/Hippo signaling is disrupted in most cases of MPM 127, 131 101. Key components of the Hippo 
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pathway include two kinases: Mammalian Sterile20-like and Large Tumor Suppressor. The 
sequential activation of these kinases leads to phosphorylation of the transcription factor YAP. 
When Hippo signaling is reduced, e.g. when NF2 signaling is disrupted, YAP phosphorylation 
decreases, leading to its nuclear localization and regulation of target genes. Rehrauer et al 
recently described progressive YAP activation during mesothelioma development in an 
experimental animal model 75 and low nuclear merlin expression in patient tumor tissues 
obtained at surgery after cisplatin/pemetrexed chemotherapy is associated with worst overall 
survival132. 
TP53 
One interesting feature of tumors bearing TP53 mutations is that the genome profile is 75% 
haploid and this profile seems to occur in younger and female patients (communicated by Dr. 
Ladanyi at International Mesothelioma Interest Group  (iMig) Meeting 2018). This suggests that 
mitosis of a haploid cell has been permitted by the loss of TP53 function, which would otherwise 
be activated by errors during the segregation of the chromosomes and lead to cell death 133. 
Interestingly these patients have also mutations in the histone methyltransferase SETDB1 
consistent with what was previously observed in one patient with MPM and two additional 
primary cancers 134. 
 
Considering that the two genes discussed above, BAP1 and NF2, are both associated with 
genetic diseases, one may ask the question why e.g. mesothelioma is not a feature of hereditary 
NF2 patients or why patients with BAP1 tumor predisposition syndrome develop tumors of non-
mesodermal derived tissue. As hypothesized by Knudson 23 years ago135, pathological conditions 
like the one induced by exposure to asbestos are necessary for stem cell proliferation by some 
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epigenetic means followed by spontaneously occurring mutations. This would be consistent with 
the observed genetic signature of mutations observed in mesothelioma where 50% of mutation 
signatures correspond to no predominant transitions or transversions and 25% correspond to CpG 
deamination 81, which are spontaneously occurring mutations. Pathological conditions induced 
by exposure to asbestos include events leading to immunosuppression favoring the growth of 
mutated cells75 indicating a possible way forward so-called “secondary prevention”, i.e. early 
tumor detection, but for the time being biomarkers for early detection are still missing136. 
However, the recent observation137 of single-layered surface mesothelial proliferations with 
deletion of CDKN2A and BAP1, likely representing mesothelioma in situ, should encourage this 
approach. 
 Altogether, experimental investigation of asbestos-induced effects and analysis of clinical 
samples have been useful to get more insights into the development of cancer following asbestos 
exposure (Figure 6); however we have highlighted several issues that still need to be addressed 
and which may also be useful to assess the toxicity of new materials, with asbestos still present, 





Figure 6. Hypothesized mechanism of mesothelioma development. After inhalation, carcinogenic fibers 
arrive in the pleural space, after passing the alveolar barrier and the visceral pleura. Due to their physical 
properties, they can not negotiate the stomata openings of lymphatic vessels of the parietal pleura and are 
retained in the pleural space, where they initiate inflammation linked to frustrated  phagocytosis and 
likely other mechanisms, leading to increased nuclear YAP, methylation of CDKN2A promoter and RNA 




An aspect worth considering is that the knowledge that has been acquired to date on asbestos 
fibers could help prepare for future challenges – in particular, with the increased production of 
materials that behave similarly to asbestos fibers. In this regard, engineered nanomaterials 
present remarkable opportunities for industrial growth and development through their 
applications in medicine, electronics and numerous other areas138.  However, there are 
considerable gaps in our knowledge concerning the hazardous effects of engineered 
nanomaterials on both human health and the environment. 
Carbon nanotubes (CNT) are being used in an increasing number of fields ranging from 
rechargeable batteries to high performance structural materials and confirmed production and use 
of carbon nanotubes was evaluated to be of ~2000 tons in 2011 139 but is rapidly increasing. 
Multi-walled carbon nanotubes (MWCNTs) are made of concentric layers of graphene sheets.  
Their cylindrical nature, exceptional mechanical strength and intrinsic physico-chemical 
properties, render their feasibility for use in a number of applications 140. Carbon nanotubes can 
exist as compact bundles if they ‘grow’ as tangles (like balls of string), and whilst CNT in such 
bundles are tubular as far as cells are concerned they are particulate. However, if CNT are 
pristine the tubules can grow straight and the CNT can adopt a fibrous, ‘high-aspect’ shape.  Not 
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surprisingly, this has raised concerns about their potential adverse health effects; indeed, in 2014, 
IARC classified MWCNT-7 (Mitsui Ltd, Japan) to category 2B: as possibly carcinogenic to 
humans.  While the National Institute for Occupational Safety and Health recommended 
exposure limit for CNT is 1 μg/m3 for the respirable size fraction (8h time weighted average)141, 
the main question in the modern era of nanotoxicology is whether nanomaterials of different 
types with a fibrous shape, conform to the classical ‘Fiber Pathogenicity Paradigm’,	  knowing 
that some induce lung cancer and mesothelioma in animal experiments.  Evidence demonstrating 
that length is a key factor in the pathogenicity of nanomaterials comes from a number of sources, 
including toxicological studies in rodents where it is possible to characterize the length of the 
fibers or define length categories and assess their effects 142-146. Additional parameters affecting 
the pathogenicity of nanofibers include diameter147 and mechanical bending stiffness141. 
The role of clearance in fiber effects is well understood and has been shown to have a 
profound effect on the biopersistence and toxicity of fibers.  Studies exploring the durability of 
single-walled and MWCNT samples in simulated phagolysosomal fluid have shown that a loss 
of mass and fiber shortening is paralled by a loss of pathogenicity 148.  Importantly, biosolubility 
in enhanced by surface modification of the carbon nanotubes thereby offering the opportunity to 
reduce the potential toxicity 149. 
The accumulation of long fibers in lung tissue can lead to numerous adverse responses which 
if sustained may result in lung pathologies as discussed for asbestos (see above). Apart from 
recent studies conducted in a large-scale MWCNT manufacturing facility in Russia, which 
revealed the accumulation of inflammatory and fibrotic biomarkers in biofluids of workers 
manufacturing MWCNTs 138, 150, lung disease directly associated with CNT exposure has not 
been widely investigated in human populations.  On the other hand, several in vivo rodent studies 
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examining the lung toxicity of CNT have revealed a pattern of effects similar to those observed 
following exposure to asbestos 151, 152 153, 154. Although of the majority of these studies were 
investigating short-term effects, short-term endpoints such as genotoxicity, inflammogenicity 
and fibrogenicity may still have the capacity to predict long-term carcinogenicity. 
To date, the presence of lung tumors in CNT-exposed animals has only been demonstrated 
following inhalation exposure to MWCNT-7 in mice pretreated with the chemical initiator 3-
methylcholanthrene 155, 156. Importantly, these effects were observed at exposures of 31 µg/mouse 
– a dose that is achievable in terms of human exposure in occupational settings. More recently, 
Suzui et al157 have also reported lung tumors and mesothelioma in rats exposed to MWCNT-N by 
trans-tracheal intrapulmonary spraying. However, it is unclear whether the data obtained using 
MWCNT-7 can be extended to other CNT due to their heterogeneity6, 141. 
In a number of studies, the pro-inflammatory response to CNT in the lung has been attributed 
to ROS generated by the presence of contaminating transition metals, or structural defects in the 
CNT generating free bonds 158.  
Alternatively CNT can increase lung ROS and oxidative stress by activating inflammatory 
cells recruited to the site of fiber deposition and frustrated phagocytosis (as discussed above for 
asbestos fibers).  The latter is accompanied by the release of oxidants and cytokines, as well as 
lysosomal destabilisation159, increasing recruitment of inflammatory cells to the lungs and 
activating the surrounding epithelial cells, leading to an inflammatory response. The ability of 
long CNT to stimulate frustrated phagocytosis in macrophages in vitro has been described in 
studies, which have shown specific length-dependent increases in the release of superoxide anion 
and pro-inflammatory cytokines 143. 
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Fibers may also be directly genotoxic by physically interfering with mitosis. Indeed, various 
genetic abnormalities including multiple mitotic spindle poles, anaphase bridges and aneuploidy 
have been observed after in vitro exposure of airway epithelial cells to single-wall CNT 160, 161. 
As described above, in addition to mesothelioma, other forms of pleural diseases, such as 
pleural effusion and pleural plaques, are recognised as asbestos exposure-related disease in the 
pleural space. The length-dependent relationship between CNT exposure in the pleural space and 
disease development has been explored using a model of direct pleural injection.  Murphy et al144  
demonstrated that CNT, like asbestos, exhibit length-dependent pathogenicity. A follow-up 
study, using purpose-synthesized silver/nickel nanowires with distinct length classes, revealed a 
cut-off length ≥5 µm for nanowires being inflammogenic145. Even though these in vivo studies on 
predicting the pathogenicity of high-aspect ratio nanomaterials in relation to asbestos fiber 
exposure in the pleural space were short term studies, they highlighted that if fiber-containing 
CNT are long enough and biopersistent they may pose an asbestos-like hazard.  Recently, this 
question was directly addressed by Chernova et al 62, who compared the carcinogenicity of long 
and short MWCNT up to 18 months after direct intrapleural injection.  This study demonstrated 
that long-fiber CNT, like asbestos, exhibit length-dependent pathogenicity and pleural disease 
including mesothelioma and pleural fibrosis.  These findings are consistent with previous in vivo 
mouse studies, where peritoneal exposure to CNT was used as a surrogate for the pleural cavity. 
Thus, in genetically-accelerated or peritoneal-exposed rodent models, CNT induced length-
dependent inflammation, accumulation of macrophages leading to the formation of 
granulomas162, and in long-term studies mesothelioma147, 163.   
While most in vivo studies that have assessed the carcinogenic hazard of CNT in rodents have 
been limited to obtaining histological evidence of tumor development, Chernova et al62 examined 
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for the first time whether the molecular mechanisms underlying long-fiber CNT-induced pleural 
carcinogenesis faithfully replicate human mesothelioma. Importantly, the results showed that 
long-fiber CNT cause sustained inflammation and progressive fibrosis of the parietal pleura, 
which in the case of both inflammatory lesions and CNT-induced tumors is accompanied by 
disruption (via epigenetic mechanisms) of the key tumor suppressor gene, Cdkn2a. Moreover, 
this finding was consistent with Nagai et al147 who had reported homozygous deletion of 
Cdkn2a/Cdkn2b in rats peritoneally exposed to MWCNTs. Notably, although co-deletion is not 
always specified as both genes are located on the same locus, this co-deletion is often found in 
human mesothelioma, as well as in murine asbestos-induced mesotheliomas. Together, these 
findings highlight a potential role for epigenetic regulation in connecting fiber (including CNT)-
induced chronic inflammation with mesothelioma development.  
In summary, due to their useful physical and chemical properties, nanomaterial manufacture is 
an area of industrial growth.  In the case of CNT, these can be manufactured as tight tangles of 
nanotubes that are essentially particles, or as high-aspect ratio ‘fibers’.  It is therefore important 
to note that the effects of CNT as particles would likely be limited to the lungs (fibrosis and 
cancer), whereas CNT as fibers would have pulmonary effects but also affect the pleura (fibrosis 
and mesothelioma) – crucially, these effects would be predicted to be length-dependent. It should 
however be noted that fiber/particle biodistribution requires further study as they might also 
reach other sites, even after inhalation (for example, as in the case of digestive cancers linked to 
asbestos exposure). In support of this, recent in vivo findings suggest long-fiber CNTs that are 
biopersistent pose an asbestos-like hazard. Therefore, the potential for human exposure and 
subsequent disease development is of major concern. 
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Open questions and future priorities 
Open questions concerning asbestos include the lack of information and reporting about 
exposure and related toxicity in some parts of the world, including community exposures 
resulting from the contamination of the environment. In some developed countries the absence of 
adequate measures to enforce primary prevention e.g. during renovation or demolition of 
structures that can release asbestos fibers was also highlighted at the iMig meeting 2018.  
Studying the toxicity of fibers is complicated by the fact that for a given mineral, at a given 
amount of material, the number of fibers will depend on their size, and the latter will also 
influence their toxicity. This has to be kept in mind for a correct interpretation of published 
studies, in addition to other factors such as surface’s adsorbed contaminants and should be taken 
into account for future studies. 
Diseases arising from exposure to asbestos or asbestos-like materials are likely to depend on 
which cells are damaged and therefore knowledge about the sites of fiber 
biodistribution/biopersistence is essential. 
In experimental models, the observation of epigenetic silencing of CDKN2A as an early event 
after exposure to asbestos fibers raises the question of the activity of chromatin modifiers and 
possibly a role for long-non-coding-RNA in asbestos carcinogenicity. 
Even if as discussed above a lot of knowledge has been acquired on the function of the 
NF2/Hippo and BAP1 pathways, it is still necessary to understand why and how these two 
pathways in particular are disrupted after exposure to carcinogenic fibers. 
The reason why some individuals develop malignant disease at an earlier age includes loss of 
function of TP53, which allows haploid cell survival, and this is a novel mechanistic aspect to 
add to the known ability of asbestos to interfere with the mitotic spindle, mostly linked to 
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polyploidy. This novel aspect requires further investigation. In this context it is worth noting 
that, in apoptosis associated speck-like protein containing a CARD (Asc) hemizygotes mice, a 
delay in mesothelioma appearance after exposure to asbestos was observed compared to wild-
type mice. Because Asc forms a complex with absent in melanoma 2 (AIM2), which senses 
DNA breaks164, it may be worthwhile to investigate whether AIM2 deficiency has an influence 
on mesothelioma development. 
Future priorities include secondary prevention of malignant disease i.e. early tumor detection 
that is completely missing for the time being.  
Altogether asbestos and new materials with similar fiber-like behavior still represent a major 
threat to human health and we suggest that mechanistic studies using standardized benchmark 
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